Dr. Franklin attended medical school at the Medical College of Ohio/ University of Toledo. After graduating medical school, Dr. Franklin earned a PhD at
Vanderbilt University in the Department of Molecular Physiology and Biophysics. His thesis focused upon the molecular biology of Insulin producing cells. Dr. Franklin continued his training at Vanderbilt as a Medical Intern.
Dr. Franklin completed his ophthalmology residency at Saint Louis University where he was chief resident in 1996-1997. He then completed his training at University of Iowa Hospitals and Clinics for vitreoretinal diseases and surgery. While at University of Iowa, Dr. Franklin secured both HEED and HEED-Knapp scholarships. His research work on an anti-vascular agent as a candidate to treat retinal diseases such as diabetic retinopathy and age-related macular degeneration was awarded the best research project by an ophthalmic physician In training at the 1999 Association of University Professors in Ophthalmology meeting.
Dr. Franklin has continued his interest and progress in the treatment of diabetic retinopathy and age-related macular degeneration (AMD) in his vitreoretinal practice. He has served as principle investigator in a number of diabetic retinopathy and AMD trials. He has presented his work at international meetings, and has published multiple manuscripts on candidate molecules to treat AMD and diabetic retinopathy. He is a founding member and chief medical officer of RFE Pharma, and has served on advisory boards for many major ophthalmic pharmaceutical companies such as Novartis, Alcon, Eyetech, Pfizer, and QLT.